Endo wrapping up Indevus tender; WHO, Schering in deal for vaccine technology;

> Endo Pharmaceuticals said that Indevus Pharmaceutical stockholders have tendered 61 million shares, or about 78 percent of the company; to wrap up the rest, it plans to make a follow-up offer expiring Friday. Report

> The World Health Organization said Tuesday that a deal with Schering-Plough will allow it to provide poor countries with improved vaccine-making technology to prepare for a possible flu pandemic. Report

>The FDA approved "deep brain stimulation" for the treatment of intractable obsessive-compulsive disorder, or OCD; it's the first time that surgically implanted electrodes have been approved for use in a psychiatric condition. Report

> Medtronic agreed to pay at least $1.03 billion to buy two closely held makers of replacement heart valves that don't require major surgery, taking the medical-device maker into a nascent market and fueling a rivalry with Edwards Lifesciences Corp. Report

> Pfizer is ending development of two medicines that had been in final human testing--one for fibromyalgia and another for generalized anxiety disorder--in order to shift funding to other experimental drugs with more potential. Report

> Swiss biotech group Basilea filed a claim against U.S. partner Johnson & Johnson over delays in launching an antibiotic to treat drug-resistant superbugs after the approval process hit a setback in Europe. Report

> AstraZeneca launched Seroquel XR for acute treatment of bipolar depression, as well as its previous indications for manic and mixed episodes. Release

> Pharma benefits manager Medco Health Solutions posted a 32 percent hike in fourth-quarter profits on growth of mail-order sales and increased demand for higher-margin generics. Report

> David Mott, non-executive director of biopharmaceutical giant Shire has topped up his stake in the company through a purchase of American Depositary Receipts (ADRs). Report

> Cell Therapeutics struck a deal to sell its remaining 50 percent stake in the cancer drug Zevalin for $18 million as it struggles to avoid running out of cash. Spectrum Pharmaceuticals--which already owns half of the drug--bought the remaining rights. Report

> CV Therapeutics has once again spurned a takeover offer from Astellas Pharma--which has done nothing to blunt the Japanese company's interest in a takeover. Report

> Eli Lilly and Daiichi Sankyo have won European approval for their blood thinner Prasugrel, one of the most closely watched therapies in late-stage development. Report

> With its stock tanking on the news that a late-stage trial of its lead drug had failed, the UK's Intercytex got a boost this morning with its announcement that it is reviewing all of its options. Report

> In what could prove to be a major breakthrough, a small "family" of monoclonal antibodies has proven effective in guarding against a range of Type A influenza strains, including the dread H5N1 flu viruses, according to an elite team of U.S. researchers. Report

> The quest for a new obesity drug took a big step forward with new research from Germany demonstrating how a drug that knocks out the FTO 'obesity gene' could help slim down the world's growing population of obese patients. Report

And Finally.. A handful of biotech companies are racing to market a new generation of tests for Down syndrome. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.